Last $0.52 USD
Change Today -0.0009 / -0.17%
Volume 157.7K
GCVRZ On Other Exchanges
Symbol
Exchange
EN Paris
New York
OTC US
Mexico
EN Paris
NASDAQ GM
As of 12:29 PM 04/16/14 All times are local (Market data is delayed by at least 15 minutes).

sanofi cvr (GCVRZ) Snapshot

Open
$0.52
Previous Close
$0.52
Day High
$0.54
Day Low
$0.52
52 Week High
10/7/13 - $2.10
52 Week Low
03/31/14 - $0.30
Market Cap
128.5M
Average Volume 10 Days
2.1M
EPS TTM
--
Shares Outstanding
249.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SANOFI CVR (GCVRZ)

sanofi cvr (GCVRZ) Details

Sanofi researches, develops, manufactures, and markets healthcare products. The company operates in three segments: Pharmaceuticals, Human Vaccines, and Animal Health. Its products include Lantus and Apidra analogs of human insulin; Insuman human insulin solutions and suspensions; Amaryl, a sulfonylurea; BGStar, iBGStar, and MyStar Extra blood glucose meters; enzyme replacement therapies, such as Cerezyme for Gaucher disease, Fabrazyme for Fabry, and Myozyme/Lumizyme for Pompe disease; Aldurazyme, for mucopolysaccharidosis Type I; Aubagio, a immunomodulator for multiple sclerosis; Taxotere, a taxane derivative for cancers; Eloxatine for colorectal cancer; and Jevtana for prostate cancer. The company’s products also comprise thrombosis medicines, such as Plavix anti-platelet agent for atherothrombotic conditions and Lovenox to prevent and treat deep vein thrombosis; and cardiovascular medicines, including Multaq anti-arrhythmic agent and Aprovel/CoAprovel for hypertension treatments. It also offers Renagel/Renvela for patients with chronic kidney disease on dialysis to treat high phosphorus levels; Synvisc and Synvisc-One viscosupplements to treat pain associated with osteoarthritis; and pediatric and influenza, adult and adolescent booster, meningitis and pneumonia, and travel and endemics vaccines. In addition, the company provides pharmaceuticals and vaccines used by veterinarians, farmers, and pet owners; consumer health care products; and generic medicines. Sanofi distributes its products through its sales force, as well as through physicians, pharmacies, hospitals, distributors, veterinaries, chemists, and wholesalers. It has strategic alliances with Bristol-Myers Squibb, Regeneron, Warner Chilcott, and Regulus Therapeutics Inc., as well as a strategic collaboration with UCB S.A. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1970 and is headquartered in Paris, France.

112,128 Employees
Last Reported Date: 03/7/14
Founded in 1970

sanofi cvr (GCVRZ) Top Compensated Officers

Chief Executive Officer, Director and Member ...
Total Annual Compensation: €3.0M
Compensation as of Fiscal Year 2013.

sanofi cvr (GCVRZ) Key Developments

Sanofi Launches Probi Digestis® in Korea

Probi has signed a distribution and supply agreement with Sanofi. Following this the Consumer Healthcare division of Sanofi Korea is making a major launch of Probi´s gut health product, Probi Digestis® starting in April 2014. Probi has already delivered products and received substantial orders for the coming quarters.

Sanofi to Resubmit Lemtrada Application for FDA Review

Sanofi and its subsidiary Genzyme announced that following constructive discussions with the U.S. Food and Drug Administration the company plans to resubmit in the second quarter its supplemental Biologics License Application (sBLA) seeking approval of Lemtrada for the treatment of relapsing forms of multiple sclerosis. The resubmission will provide information to specifically address issues noted by the FDA in its December 27, 2013 Complete Response Letter. Genzyme had previously announced its intention to appeal the FDA's Complete Response Letter. In light of the planned resubmission, the company does not expect to pursue an appeal at this time.

Sanofi Eyes Acquisitions In Africa

Sanofi (ENXTPA:SAN) is eyeing more acquisition opportunities in Africa to increase its key business units, such as consumer and animal health products, in the country, First Word Pharma reported, citing Chief Executive Officer, Chris Viehbacher.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GCVRZ:US $0.52 USD -0.0009

GCVRZ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bayer AG €93.23 EUR +1.91
Gilead Sciences Inc $69.23 USD +1.06
GlaxoSmithKline PLC 1,564 GBp +16.50
Merck & Co Inc $56.13 USD +0.075
Novo Nordisk A/S kr235.60 DKK +4.90
View Industry Companies
 

Industry Analysis

GCVRZ

Industry Average

Valuation GCVRZ Industry Range
Price/Earnings 26.8x
Price/Sales 3.0x
Price/Book 1.7x
Price/Cash Flow 14.9x
TEV/Sales 2.3x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SANOFI CVR, please visit www.sanofi-aventis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.